Cubist Systematic Strategies, LLC Humanigen, Inc Transaction History

Cubist Systematic Strategies, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.76 - $3.33 $82,248 - $155,617	-46,732 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.81 - $3.97 $81,911 - $179,662	-45,255 Reduced 49.2%	46,732 $141,000
Q4 2021 Feb 14, 2022	BUY	$3.66 - $8.22 $336,350 - $755,409	91,899 Added 104430.68%	91,987 $342,000
Q3 2021 Nov 15, 2021	SELL	$5.93 - $17.83 $145,949 - $438,831	-24,612 Reduced 99.64%	88 $1,000
Q2 2021 Aug 16, 2021	BUY	$13.54 - $22.74 $36,233 - $60,852	2,676 Added 12.15%	24,700 $429,000
Q1 2021 May 17, 2021	BUY	$12.91 - $23.83 $284,329 - $524,831	22,024 New	22,024 $421,000

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.